View Item 

Show simple item record

Calcium Phosphate Metabolism and Cardiovascular Disease in Patients with Chronic Kidney Disease
dc.contributor.authorBlock, Geoffreyen_US
dc.contributor.authorPort, Friedrich K.en_US
dc.date.accessioned2010-06-01T20:41:13Z
dc.date.available2010-06-01T20:41:13Z
dc.date.issued2003-03en_US
dc.identifier.citationBlock, Geoffrey; Port, Friedrich K (2003). "Calcium Phosphate Metabolism and Cardiovascular Disease in Patients with Chronic Kidney Disease." Seminars in Dialysis 16(2): 140-147. <http://hdl.handle.net/2027.42/73791>en_US
dc.identifier.issn0894-0959en_US
dc.identifier.issn1525-139Xen_US
dc.identifier.urihttps://hdl.handle.net/2027.42/73791
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=12641878&dopt=citationen_US
dc.format.extent178994 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Science Incen_US
dc.rights2003 Blackwell Publishingen_US
dc.titleCalcium Phosphate Metabolism and Cardiovascular Disease in Patients with Chronic Kidney Diseaseen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUniversity Renal Research and Education Association, Ann Arbor, Michiganen_US
dc.contributor.affiliationotherDenver Nephrology Associates, Denver, Colorado, anden_US
dc.identifier.pmid12641878en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/73791/1/j.1525-139X.2003.160301.x.pdf
dc.identifier.doi10.1046/j.1525-139X.2003.160301.xen_US
dc.identifier.sourceSeminars in Dialysisen_US
dc.identifier.citedreferenceZoccali C: Cardiovascular risk in uraemic patients is it fully explained by classical risk factors? Nephrol Dial Transplant 15: 454 457, 2000en_US
dc.identifier.citedreferenceLongenecker JC, Coresh J, Powe NR, Levey AS, Fink N, Martin A, Klag MJ: Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE study. J Am Soc Nephrol 13: 1918 1927, 2002en_US
dc.identifier.citedreferenceParfrey PS: Is renal insufficiency an atherogenic state? Reflections on prevalence, incidence and risk. Am J Kidney Dis 37: 154 156, 2001en_US
dc.identifier.citedreferenceFoley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE: Clinical and echocardiographic disease in patients starting end stage renal disease therapy. Kidney Int 47: 186 192, 1995en_US
dc.identifier.citedreferenceHemmelgarn BR, Ghali WA, Quan H, Brant R, Norris CM, Taub KJ, Knudtson ML: Poor long term survival after coronary angiography in patients with renal insufficiency. Am J Kidney Dis 37: 64 72, 2001en_US
dc.identifier.citedreferenceRostand SG, Drueke TB: Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 56: 383 392, 1999en_US
dc.identifier.citedreferenceDavies MR, Hruska KA: Pathophysiologic mechanisms of vascular calcification in end stage renal disease. Kidney Int 60: 472 479, 2001en_US
dc.identifier.citedreferenceCozzolino M, Dusso A, Slatopolsky E: Role of calcium-phosphate product and bone associated proteins on vascular calcification in renal failure. J Am Soc Nephrol 12: 2511 2516, 2001en_US
dc.identifier.citedreferenceJono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM: Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87: 10 17, 2000en_US
dc.identifier.citedreferenceGiachelli CM, Jono S, Shioi A, Nishizawa Y, Mori K, Morii H: Vascular calcification and inorganic phosphate. Am J Kidney Dis 38: S34 S37, 2001en_US
dc.identifier.citedreferenceShioi A, Taniwaki H, Jono S, Okuno Y, Koyama H, Mori K, Nishizawa Y: Monckebergs medial sclerosis and inorganic phosphate in uremia. Am J Kidney Dis 38: S47 S49, 2001en_US
dc.identifier.citedreferenceMoe SM, O'Neill KD, Duan D, Ahmed S, Chen NX, Leapman SB, Fineberg N, Kopecky K: Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 61: 638 647, 2002en_US
dc.identifier.citedreferencePrice PA, Faus SA, Williamson MK: Warfarin induced artery calcification is accelerated by growth and vitamin D. Arterioscler Thromb Vasc Biol 20: 317 327, 2000en_US
dc.identifier.citedreferenceGuerin AP, London GM, Marchais SJ, Metivier F: Arterial stiffening and vascular calcifications in end stage renal disease. Nephrol Dial Transplant 15: 1014 1021, 2000en_US
dc.identifier.citedreferenceBlacher J, Guerin AP, Pannier B, Marchais SJ, London AM: Arterial calcifications, arterial stiffness, and cardiovascular risk in end stage renal disease. Hypertension 38: 938 942, 2001en_US
dc.identifier.citedreferenceBlacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM: Impact of aortic stiffness on survival in end stage renal disease. Circulation 99: 2434 2439, 1999en_US
dc.identifier.citedreferenceLondon GM: Alterations of arterial function in end stage renal disease. Nephron 84: 111 118, 2000en_US
dc.identifier.citedreferenceAsmar R: Arterial Stiffness and Pulse Wave Velocity: Clinical Applications. Paris: Elsevier, 1999en_US
dc.identifier.citedreferenceO'Rourke MF: Wave travel and reflection in the arterial system. J Hypertens 17: S45 S47, 1999en_US
dc.identifier.citedreferenceCovic A, Goldsmith D, Panaghiu L, Covic M, Sedor J: Analysis of the effect of hemodialysis on peripheral and central arterial pressure waveforms. Kidney Int 57: 2634 2643, 2000en_US
dc.identifier.citedreferenceGoldsmith D, MacGinley R, Smith A, Covic A: How important and how treatable is vascular stiffness as a cardiovascular risk factor in renal failure? Nephrol Dial Transplant 17: 965 969, 2002en_US
dc.identifier.citedreferenceKlassen PS, Lowrie EG, Reddan DN, DeLong ER, Coladonato JA, Szezech LA, Lazarus JM, Owen WF: Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA 287: 1548 1555, 2002en_US
dc.identifier.citedreferenceTozawa M, Iseki K, Iseki C, Takishita S: Pulse pressure and risk of total mortality and cardiovascular events in patients on chronic hemodialysis. Kidney Int 61: 717 726, 2002en_US
dc.identifier.citedreferenceRaggi P: Coronary calcium on electron beam tomography imaging as a surrogate marker of coronary artery disease. Am J Cardiol 87: 27A 34A, 2001en_US
dc.identifier.citedreferenceSchwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G, Mall G, Amann K: Morphology of coronary atherosclerotic lesions in patients with end stage renal failure. Nephrol Dial Transplant 15: 218 223, 2000en_US
dc.identifier.citedreferenceBlock GA, Raggi P, Mehta R, Lindbergh J, Dreisbach A, Spiegel DM: Cardiovascular calcification in new hemodialysis patients: assessment with electron beam computed tomography abstract. J Am Soc Nephrol 13: 442A, 2002en_US
dc.identifier.citedreferenceRaggi P, Boulay A, Chasan-Tabar S, Amin NS, Dillon MA, Burke SK, Chertow GM: Cardiac calcification in adult hemodialysis patients. J Am Coll Cardiol 39: 695 701, 2002en_US
dc.identifier.citedreferenceMourad J, Pannier B, Blacher J, Rudnichi A, Benetos A, London GM, Safar ME: Creatinine clearance, pulse wave velocity, carotid compliance and essential hypertension. Kidney Int 59: 1834 1841, 2001en_US
dc.identifier.citedreferenceKonings CJAM, Dammers R, Rensma PL, Kooman JP, Hoeks APG, Kornet L, Gladziwa U, van der Sande FM, Levey AS: Arterial wall properties in patients with renal failure. Am J Kidney Dis 39: 1206 1212, 2002en_US
dc.identifier.citedreferenceKates DM, Sherrard DJ, Andress DL: Evidence that serum phosphate is independently associated with serum PTH in patients with chronic renal failure. Am J Kidney Dis 30: 809 813, 1997en_US
dc.identifier.citedreferenceFelsenfeld AJ, Rodriguez M: Phosphorus, regulation of plasma calcium, and secondary hyperparathyroidism: a hypothesis to integrate a historical and modern perspective. J Am Soc Nephrol 10: 878 890, 1999en_US
dc.identifier.citedreferenceMartinez I, Saracho R, Montenegro J, Llach F: The importance of dietary calcium and phosphorus in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis 29: 496 502, 1997en_US
dc.identifier.citedreference33. National Kidney Foundation: K DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39: S143 S156, 2002en_US
dc.identifier.citedreferenceKausz AT, Khan SS, Abichandani R, Kazmi WH, Obrador GT, Ruthazer R, Pereira BJG: Management of patients with chronic renal insufficiency in the northeastern United States. J Am Soc Nephrol 12: 1501 1507, 2001en_US
dc.identifier.citedreferenceJohnson CA, McCarthy J, Bailie GR, Deane J, Smith S: Analysis of renal bone disease treatment in dialysis patients. Am J Kidney Dis 39: 1270 1277, 2002en_US
dc.identifier.citedreferenceCoco M, Rush H: Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 36: 1115 1121, 2000en_US
dc.identifier.citedreferenceQi Q, Monier-Faugere M-C, Geng Z, Malluche HH: Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis 26: 622 631, 1995en_US
dc.identifier.citedreferenceGonzalez EA: The role of cytokines in skeletal remodelling: possible consequences for renal osteodystrophy. Nephrol Dial Transplant 15: 945 950, 2000en_US
dc.identifier.citedreferenceHruska KA: Pathophysiology of renal osteodystrophy. Pediatr Nephrol 14: 640, 2000en_US
dc.identifier.citedreferenceBurnett JR, Vasikaran SD: Cardiovascular disease and osteoporosis: is there a link between lipids and bone? Ann Clin Biochem 39: 203 210, 2002en_US
dc.identifier.citedreferencePrice PA, Buckley JR, Williamson MK: The amino bisphosphonate ibandronate prevents vitamin D toxicity and inhibits vitamin D induced calcification of arteries, cartilage, lungs and kidneys in rats. J Nutr 131: 2910 2915, 2001en_US
dc.identifier.citedreferenceFan SL, Cunningham J: Bisphosphonates in renal osteodystrophy. Curr Opin Nephrol Hypertens 10: 581 588, 2001en_US
dc.identifier.citedreferenceBlock GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31: 607 617, 1998en_US
dc.identifier.citedreferenceGoodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary artery calcification in young adults with end stage renal disease who are undergoing dialysis. N Engl J Med 342: 1478 1483, 2000en_US
dc.identifier.citedreferenceGanesh SK, Stack AG, Levin NW, Hulbert-Shearon TE, Port FK: Association of elevated serum PO4, CaxPO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12: 2131 2138, 2001en_US
dc.identifier.citedreferenceOkechukwu CN, Lopes AA, Stack AG, Feng S, Wolfe RA, Port FK: Impact of years of dialysis therapy on mortality risk and the characteristics of longer term dialysis survivors. Am J Kidney Dis 39: 533 538, 2002en_US
dc.identifier.citedreferenceFoley RN, Parfrey PS, Harnett JD, Kent GM, Hu L, O'Dea R, Murray DC, Barre PE: Hypocalcemia, morbidity and mortality in end stage renal disease. Am J Nephrol 16: 386 393, 1996en_US
dc.identifier.citedreferenceChertow GM, Lowrie EG, Lew NJ, Lazarus JM: Mineral metabolism and mortality in hemodialysis abstract. J Am Soc Nephrol 11: 560A, 2000en_US
dc.identifier.citedreferenceBleyer AJ, Burke SK, Dillon MA, Garrett B, Kant KS, Lynch D, Rahman SN, Schoenfeld P, Teitelbaum I, Zeig S, Slatopolsky E: A comparison of the calcium free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 33: 694 701, 1999en_US
dc.identifier.citedreferenceChertow GM, Burke SK, Raggi P: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62: 245 252, 2002en_US
dc.identifier.citedreferenceKimura K, Saika Y, Otani H, Fuji R, Mune M, Yukawa S: Factors associated with calcification of the abdominal aorta in hemodialysis patients. Kidney Int 56: S238 S241, 1999en_US
dc.identifier.citedreferenceLondon GM, Marchais SJ, Safar ME, Genest AF, Guerin AP, Metivier F, Chedid K, London AM: Aortic and large artery compliance in end stage renal failure. Kidney Int 37: 137 142, 1990en_US
dc.identifier.citedreferenceCoburn JW, Elangovan L: Prevention of metabolic bone disease in the pre-end stage renal disease setting. J Am Soc Nephrol 9: S71 S77, 1998en_US
dc.identifier.citedreferenceHamdy NAT, Kanis JA, Beneton MNC, Brown CB, Juttmann JR, Jordans JGM, Josse S, Meyrier A, Lins RL, Fairey IT: Effect of afacalcidol on natural course of renal bone disease in mild to moderate renal failure. Br Med J 310: 358 363, 1995en_US
dc.identifier.citedreferenceLorenzo V, Martin M, Rufino M, Jimenez A, Sci B, Malo AM, Sanchez E, Hernandez D, Rodriguez M, Torres A: Protein intake, control of serum phosphorus, and relatively low levels of parathyroid hormone in elderly hemodialysis patients. Am J Kidney Dis 37: 1260 1266, 2001en_US
dc.identifier.citedreferenceIndridsan OS, Quarles LD: Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Kidney Int 57: 282 292, 2000en_US
dc.identifier.citedreferenceGoodman WG: Calcimimetic agents and secondary hyperparathyroidism: treatment and prevention. Nephrol Dial Transplant 17: 204 207, 2002en_US
dc.identifier.citedreferenceGoodman WG, Hladik GA, Turner SA, Blaisdell PW, Goodkin DA, Liu W, Barri YM, Cohen RM, Coburn JW: The calcimimetic agent AMG073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism abstract. J Am Soc Nephrol 13: 1017 1024, 2002en_US
dc.identifier.citedreferenceSherrard DJ: Manipulating the calcium receptor. J Am Soc Nephrol 13: 1124 1125, 2002en_US
dc.identifier.citedreferenceSeliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ, Stehman-Breen CO: HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 61: 297 304, 2002en_US
dc.identifier.citedreferenceKestenbaum B, Gillen DL, Sherrard DJ, Seliger S, Ball A, Stehman-Breen C: Calcium channel blocker use and mortality among patients with end stage renal disease. Kidney Int 61: 2157 2164, 2002en_US
dc.identifier.citedreferencevan de Poll SW, Delsing DJ, Jukema JW, Princen HM, Havekes LM, Puppels GJ, van der Laarse A: Raman spectroscopic investigation of atorvastatin, amlodipine and both on atherosclerotic plaque development in APOE 3 Leiden transgenic mice. Atherosclerosis 164: 65 71, 2002en_US
dc.identifier.citedreferenceGuerin AP, Blacher J, Pannier B, Marchais SJ, Safar M, London GM: Impact of aortic stiffness attenuation on survival of patients in end stage renal failure. Circulation 103: 987 992, 2001en_US
dc.identifier.citedreferenceYlitalo R: Bisphosphonates and atherosclerosis. Gen Pharmacol 35: 287 296, 2002en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1525-139X.2003.160301.x.pdf
Size:
174.7KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.